Thursday, January 04, 2018 -- ALS is a debilitating and ultimately deadly neural disease that has few treatments and no cure.
Saturday, August 26, 2017 -- Some Canadians diagnosed with amoyotrophic lateral sclerosis, or ALS, are spending thousands of dollars to obtain a new drug from abroad they hope will slow the progress of the terminal disease.
Monday, January 15, 2018 -- Researchers at Western University believe they have found a common link between the degenerative brain condition CTE, and a variant of ALS, or Lou Gehrig’s disease.
Thursday, June 08, 2017 -- (Natural News) With so much attention being given to global warming these days it easy to blame our changing climate for everything that is going wrong in this world. However, new research by scientists from the University of Queensland revealed that man-made substances and chemicals, not global warming, are the cause of mass contamination of... Read More
Friday, May 19, 2017 -- Newly discovered genetic mutations are providing clues about how this disorder relentlessly destroys motor neurons and robs people of their mobility. The findings may lead to drug therapies for a... -- Read more on ScientificAmerican.com
Thursday, August 10, 2017 -- Artificially intelligent machines could analyze huge databases to find potential targets for the devastating disease -- Read more on ScientificAmerican.com
Monday, September 18, 2017 -- Brainstorm's NurOwn, a potential stem cell therapy now at phase 3, aims to promote the survival of motor neurons in people with ALS.
Wednesday, June 14, 2017 -- Many cases of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are associated with the C9ORF72 gene, which is known to encode toxic molecules, dipeptide repeat proteins, that interfere with the proper splicing of mRNA. Exactly how these toxic molecules could gum up the splicing mechanism, however, has been unclear. The sticking point, new results indicate, is a small nuclear ribonucleoprotein particle, also known as a snRNP ("snurp") that is needed for the proper functioning of the spliceosome, the cell’s mRNA-splicing machine. A new paper that appeared June 13 in Cell Reports, in an article entitled “Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients,” describes how researchers from Harvard Medical School
Tuesday, May 23, 2017 -- Researchers praise a “breakthrough” treatment to improve brain function and longevity for patients with the incurable Lou Gehrig’s disease, also known as ALS.
Tuesday, November 21, 2017 -- (Reuters) - Cytokinetics Inc will stop developing one of its treatments for ALS, which afflicts Stephen Hawking, after the drug failed in a late-stage trial, the company said on Tuesday, sending its shares tumbling about 35 percent.
Wednesday, January 03, 2018 -- (Reuters) - Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.
Sunday, September 10, 2017 -- For the first time ever, it could be possible to 'grow' motor neurons without stem cells.
Monday, July 17, 2017 -- Researchers at the University of Sheffield discovered a mechanism driving neuron death and reversed neurodegeneration in rodents and human cells. A new study published in Nature Neuroscience describes a previously unknown mechanism behind the death of neurons in neurodegenerative disease. The ... This awesome article British Scientists Find a DNA Mechanism to Prevent ALS and Alzheimer’s appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Tuesday, August 08, 2017 -- Radicava is supplied as a 30mg/100mL solution for intravenous infusion in single-dose polypropylene bags.
Monday, June 05, 2017 -- NewsALS.AI, a personalized drug discovery and biomarker development platform, is intended to advance the discovery of new drugs and repurpose existing ones for amyotrophic lateral sclerosis (ALS) and personalized treatment for ALS patients.Contributed Author: Insilico Medicine, Inc.Topics: Drug Development
Tuesday, May 23, 2017 -- Mexiletine reduces the frequency and severity of muscle cramps in people with ALS- a key source of pain particularly early in the disease.
Monday, November 20, 2017 -- Canadian researchers have discovered an effective medication for the treatment of individuals with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
Thursday, June 01, 2017 -- A single-domain antibody-based approach may help treat ALS by facilitating axon regeneration.
Friday, July 21, 2017 -- BrainStorm Cell Therapeutics has won a $15.9 million grant from California’s regenerative medicine agency toward a Phase III trial of its amyotrophic lateral sclerosis (ALS) cell therapy candidate NurOwn ® . The governing board of the California Institute for Regenerative Medicine (CIRM) approved the grant yesterday—the second instance of CIRM funding a clinical trial program focused on ALS. “CIRM’s mission is to accelerate stem cell treatments to patients with unmet medical needs, and, in keeping with this mission, our objective is to find a treatment for patients ravaged by this neurologic condition for which there is currently no cure,” Maria Millan, M.D., CIRM’s interim president and CEO, said in a statement. NurOwn uses mesenchymal stem cells that are converted
Monday, May 22, 2017 -- ALS is a neurodegenerative disease in which motor neurons in the brain and spinal cord are damaged. As ALS progresses, neurons are unable to send impulses to muscles, making voluntary muscle movement difficult, including standing, walking and sitting, as well as speaking and swallowing.